Artelo Biosciences reports 2022 EPS ($3.56) vs. (5.97) last year

"We achieved meaningful clinical progress throughout 2022," stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. "Importantly, we completed enrollment of the first three cohorts in our Cancer Appetite Recovery Study, evaluating ART27.13 for the treatment of cancer-related anorexia and weight loss. Given ART27.13’s better-than-expected safety profile and absence of drug-related grade three or four toxicity, we elected to advance to a fourth cohort at a 650-microgram dose. Since enrollment of the fourth cohort is now complete, we are awaiting the final patient’s results to be fully evaluable before initiation of the Phase 2a stage of CAReS, which is anticipated in April 2023. We are well funded into the second half of 2024 and intend to aggressively advance our product pipeline to develop new treatment options for people suffering from cancer and other debilitating diseases."